Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions

Emerging evidence suggests that ADP-ribosylation factor like-4c (Arl4c) may be a potential choice for cancer treatment. However, its role in pancreatic cancer, especially in tumor-stroma interactions and drug resistance, is still unknown. In the current study, we examined the proliferation and drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xin, Zhang, Yanzhen, Qian, Weikun, Han, Liang, Li, Wei, Duan, Wanxing, Wu, Zheng, Wang, Zheng, Ma, Qingyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609020/
https://www.ncbi.nlm.nih.gov/pubmed/34849465
http://dx.doi.org/10.1016/j.isci.2021.103400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609020/
https://www.ncbi.nlm.nih.gov/pubmed/34849465
http://dx.doi.org/10.1016/j.isci.2021.103400

Ejemplares similares